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Abstract
Background: Reduced glomerular filtration rate is an important predictor of cardiovascular disease and death. Genetic
polymorphisms, particularly in genes involved in the renin-angiotensin system (RAS), may influence the rate of renal
function decline.
Methodology/Principal Findings: We examined the relation between specific single nucleotide polymorphisms (SNPs),
including those in the RAS, apolipoprotein E and alpha-adducin, and renal function decline assessed by estimated
glomerular filtration rate (eGFR) over an 11-year period in 2578 Caucasian participants of the Nurses’ Health Study. Logistic
regression was used to examine the associations between genotype and risk of eGFR decline of $25%.
Results: After 11 years between creatinine measurements, the eGFR declined by $25% in 423 of 2578 (16%) women. The
angiotensinogen (AGT) A-20C polymorphism was associated with a higher risk of renal function decline when two risk
alleles were present than if one or no alleles were present (CC vs AA and AC) OR 1.83 (95% CI 1.02–3.26; p=0.04). The
angiotensin II type 1 receptor (AT1R) A1166C polymorphism was marginally associated with a higher risk of renal function
decline when two risk alleles were present (CC vs AA, OR=1.41; 95% CI 0.98–2.01; p=0.06). The alpha-adducin G460W
polymorphism was associated with a lower risk of renal function decline when any number of risk alleles were present (WG
vs GG, OR=0.78, 95% CI 0.61–0.99, p=0.04; WW vs GG, OR=0.46; 95% CI 0.20–1.07, p=0.07). Linear regression analysis with
change in eGFR as the outcome showed a larger decline of 3.5 (95% CI 0.5 to 6.4, p=0.02) ml/min/1.73 m
2 in AGT A-20C CC
homozygotes. No other polymorphisms were significantly associated with renal function decline or absolute change in
eGFR over the study period.
Conclusions: Genetic variants in the angiotensinogen, angiotensin II type 1 receptor and alpha-adducin genes may
contribute to loss of renal function in the general female Caucasian population.
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Introduction
Reduced glomerular filtration rate is an important predictor of
cardiovascular disease and death, in high-risk groups as well as in
the general population [1,2]. Even in the absence of identifiable
risk factors for renal function decline, such as hypertension or
diabetes, kidney dysfunction may develop slowly over decades.
Genetic polymorphisms may confer increased risk of renal decline
either through direct effects or by increasing susceptibility to
environmental factors.
Blockade of the renin-angiotensin-system (RAS) [3–5] has been
shown to slow renal function decline in individuals with renal
disease, providing evidence that activation of the RAS may
promote a more rapid loss of GFR. Because the activity of the
RAS is intimately related to systemic blood pressure, dozens of
studies have examined the relation between blood pressure or
hypertension and polymorphisms in RAS-related genes, but the
findings have been inconsistent [6,7].
Polymorphisms in other genes, specifically alpha-adducin and
apolipoprotein, may also promote renal function decline. In-
creased alpha-adducin activity influences sodium handling and
glomerular hemodynamics in experimental animals and is
associated with hypertension in humans [8,9]. Conversely,
compared to other apolipoprotein E types, the epsilon 4 variant
lowers the risk of adverse renal outcomes [10]. Therefore,
functional genetic variation in these genes may be involved in
the loss of renal function over time.
Most prior investigations of these polymorphisms and renal
function have focused on populations with established chronic
kidney disease or heart disease. In contrast, their association with
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4787renal function decline in a general population without established
renal disease has not been extensively studied. We examined these
relations over an 11 year period in 2,578 Caucasian participants of
the Nurses’ Health Study.
Results
The mean age of the women in this sub-cohort in 1989 was 56.3
years (median, 56; interquartile range, 51–62) and the mean BMI
was 25.5 kg/m
2 (median, 24.4; interquartile range 22.0–27.8).
There were no significant differences in baseline age or BMI across
any genotype (data not shown). The mean creatinine at baseline
was 0.76 mg/dl and the mean eGFR at baseline was 86 ml/min/
1.73 m
2.
The genotype frequency for each polymorphism is shown in
Table 1. Other than the ACE I/D polymorphism (p=0.04), no other
SNP deviated significantly from Hardy-Weinberg equilibrium.
During 11 years between creatinine measurements, the eGFR
declined 25% or greater in 423 of 2578 (16%) women. Age-
adjusted associations between polymorphisms and a $25%
decline in eGFR are shown in Table 2. The angiotensinogen
AGT A-20C polymorphism was associated with a higher risk of
renal function decline when two risk alleles were present than if
one or no alleles were present (CC vs AA and AC) OR 1.83 (95%
CI 1.02–3.26; p=0.04). The angiotensin II receptor type 1 (AT1R)
A1166C polymorphism was marginally associated with a higher
risk of renal function decline when two risk alleles were present
(CC vs AA, OR=1.41; 95% CI 0.98–2.01; p=0.06). The alpha-
adducin G460W polymorphism was associated with a lower risk of
renal function decline when any number of risk alleles were
present (WG vs GG, OR=0. 78, 95% CI 0.61–0.99; p=0.04;
WW vs GG, OR=0.46; 95% CI 0.20–1.07; p=0.07); the OR for
the dominant model was 0.75 (95% CI 0.59–0.95; p=0.02).
Linear regression analysis with change in eGFR as the outcome
showed a larger decline of 3.5 (95% CI 0.5 to 6.4; p=0.02) ml/
min/1.73 m
2 in AGT A-20C CC homozygotes. No other
polymorphisms were significantly associated with renal function
decline or absolute change in eGFR over the study period.
We explored potential interactions with BMI and history of
hypertension. Only the ORs for dominant models for alpha-
adducin G460W varied by BMI and HTN. The OR for eGFR
decline $25% was 0.99 (0.72–1.35) for BMI,25 kg/m
2 and 0.52
(0.36–0.77) for BMI$25 (p, interaction=0.06). The OR for eGFR
decline $25% was 0.65 (0.49–0.88) for no history of hypertension
and 0.99 (0.65–1.49) for a history of hypertension (p, interac-
tion=0.03).
Discussion
We found several polymorphisms associated with altered risk of
renal function decline over an 11-year period. Homozygosity for
the angiotensinogen AGT A-20C polymorphism was associated
with an 83% increased odds of a $25% decline in eGFR over 11
years. Homozygosity for the AT1R A1166C polymorphism was
marginally associated with a 41% increased odds of a $25%
decline in eGFR over 11 years. The alpha-adducin G460W
polymorphism was associated with a 25% decreased odds of a
$25% decline in eGFR over 11 years.
Genetic susceptibility may play an important role in rate of renal
function decline. Clustering of renal disease occurs within families,
Table 1. Genotype frequencies among 2578 Caucasian women from the Nurses’ Health Study.
Genotype Genotype frequency (%) p-value*
AGT M235T M/M M/T T/T
881 (34.2) 1184 ( 45.9) 443 (17.2) 0.19
AGT A-20C A/A A/C C/C
1750 (67.9) 692 (26.8) 62 (2.4) 0.51
ACE I/D I/I I/D D/D
515 (20.0) 1122 (43.5) 726 (28.2) 0.04
AT1R A1166C A/A A/C C/C
1259 (48.8) 1017 (39.4) 233 (9.0) 0.18
AS T-344C T/T T/C C/C
739 (28.7) 1182 (45.8) 531 (20.6) 0.15
Adducin G460W G/G G/W W/W
1709 (66.3) 707 (27.4) 67 (22.6) 0.59
APOE C334T C/C C/T T/T
54 (2.1) 594 (23.0) 1860 (72.1) 0.42
APOE C472T C/C C/T T/T
2126 (82.5) 331 (12.8) 18 (0.7) 0.20
APOE (Summ. Score) E2/E2 (22) E3/E2 (21) E4/E2 (0) E3/E3 (0) E3/E4 (+1) E4/E4 (+2)
18 (0.7) 273 (10.6) 58 (2.2) 1537 (59.6) 528 (20.5) 46 (1.8)
Totals do not equal 2578 because of variable numbers with missing genotypes.
*Chi-square test for deviation from Hardy-Weinberg equilibrium.
ACE, Angiotensin Converting Enzyme.
AGT, Angiotensinogen.
AT1R, Angiotensin II Receptor Type 1.
AS, Aldosterone Synthase.
APOE, apolipoprotein E.
doi:10.1371/journal.pone.0004787.t001
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15]. Like many complex disorders, it is unlikely that a single genetic
polymorphism will explain all susceptibility to accelerated renal
function decline. However, certain genetic alterations that affect the
expression or function of a key protein product, so called functional
polymorphisms, may influence pathological processes either promot-
ed or prevented by that key protein [16]. Randomized controlled
trials with agents that interrupt the renin-angiotensin-system (RAS)
[3–5] have demonstrated a slowing of renal function decline in
individuals with renal disease, providing strong evidence that
activation of the RAS may promote a more rapid loss of GFR in
patients with renal disease. While speculative, it is intriguing to
consider the possibility that more directed pharmacologic therapy
might derive from findings like these; for example, blockade of the
AT1R with angiotensin receptor blockade might be especially
beneficial in these patients [17].
Polymorphisms in the angiotensinogen gene (M235T and A-
20C) have been associated with hypertension [18,19], faster
progression to ESRD [20], susceptibility to nephropathy in
patients with type I diabetes mellitus [21], and progression of
renal dysfunction in adults [22] and children [23] with IgA
nephropathy. There was no association found in two populations
with type II diabetes [24,25]. We found an association between the
A-20C polymorphism and increased risk of renal function decline
and no association with the other angiotensinogen polymorphism
in our population.
Angiotensin II type 1 receptor (AT1R) polymorphisms may
influence intrarenal angiotensin II activity. Healthy Caucasian
carriers of the A1166C polymorphism showed 7% lower basal
GFR and 17% lower basal renal plasma flow, as well as enhanced
increases in GFR following treatment with the AT1R blocker
losartan [17]. Rate of progression to ESRD in patients with
nephropathies of various etiologies was more rapid in individuals
homozygous for the AT1R A1166C polymorphism [26,27]. Our
study found a similar association between homozygosity for the
AT1R A1166C polymorphism and an accelerated rate of renal
function decline.
The deletion polymorphism in intron 16 of the ACE gene has
been correlated with increased plasma ACE activity [28]. An
increased risk of progression of renal disease associated with the
ACE-D allele has been reported in some populations with renal
disease [20,29] but not in others [30,31]. A genetic predisposition
to diabetic nephropathy based on the DD genotype has been
reported in several studies [32–34], but remains controversial [35].
We found no association between the insertion/deletion polymor-
phism of the ACE gene and accelerated renal function decline.
Aldosterone, independent of angiotensin II, has been associated
with renal dysfunction and glomerulosclerosis in remnant kidney
rat models and glomerular hyperfiltration in humans with primary
aldosteronism [36,37]. Past studies of aldosterone synthase gene
polymorphisms and hypertension have been mixed [38–41] and
no prior study has found an association between the aldosterone
synthase polymorphism and progression of renal disease [20]. We
similarly found no association with the T-344C aldosterone
synthase polymorphism and accelerated renal function decline.
Adducin is a membrane cytoskeleton-associated protein con-
sisting of an alpha subunit and either a beta-or gamma-subunit
that promotes the assembly of the spectrin-actin network. In rats
and humans, mutations of the alpha-adducin subunit lead to the
stimulation of Na(+), K(+)-ATP-ase activity in renal tubular cells,
increased renal Na(+) reabsorption and, subsequently, low-renin
hypertension [8,9]. A familial aggregation study demonstrated that
low renin hypertension was associated with the alpha-adducin
G460W polymorphism [42]. In a study of 260 ESRD patients
matched to controls, the time from diagnosis with renal disease to
onset of ESRD was shorter for patients homozygous for
tryptophan (Trp) at the glycine to tryptophan (G460W) polymor-
phism versus those homozygous for glycine (Gly) [43]. The alpha-
Table 2. Association between Gene Polymorphisms and Risk of $25% Decline in GFR Over 11 Years, Adjusted for Age.
Dose Response Model (OR, 95%CI) Dominant Model (OR, 95%CI) Recessive Model (OR, 95%CI)
AGT M235T M/T: 1.02 (0.81–1.30) 1.00 (0.80–1.24) 0.91 (0.69–1.21)
T/T: 0.92 (0.68–1.27)
AGT A-20C A/C: 0.99 (0.78–1.26) 1.05 (0.84–1.32) 1.83 (1.02–3.26)
C/C: 1.82 (1.02–3.27)
ACE I/D I/D: 0.87 (0.66–1.15) 0.90 (0.69–1.16) 1.03 (0.81–1.30)
D/D: 0.94 (0.69–1.26)
AT1R A1166C A/C: 1.17 (0.94–1.47) 1.22 (0.98–1.50) 1.31 (0.93–1.84)
C/C: 1.41 (0.98–2.01)
AS T-344C T/C: 0.86 (0.68–1.11) 0.87 (0.70–1.10) 0.97 (0.75–1.26)
C/C: 0.89 (0.66–1.20)
Adducin G460W G/W: 0.78 (0.61–0.99) 0.75 (0.59–0.95) 0.49 (0.21–1.14)
W/W: 0.46 (0.20–1.07)
APOE Relative Risk per Unit Increase in summary score:
1.08 (0.91–1.28)
AGT, Angiotensinogen; reference=M/M (dose response and dominant models) or M/M+M/T (recessive model).
AGT, Angiotensinogen; reference=A/A (dose response and dominant models) or A/A+A/C (recessive model).
ACE, Angiotensin Converting Enzyme; reference=I/I (dose response and dominant models) or I/I+I/D (recessive model).
AT1R, Angiotensin II Type 1 Receptor; reference=A/A (dose response and dominant models) or A/A+A/C (recessive model).
AS, Aldosterone Synthase; reference=T/T (dose response and dominant models) or T/T+T/C (recessive model).
Adducin G460W; reference=G/G (dose response and dominant models) or G/G+G/W (recessive model).
APOE, Apolipoprotein A; reference=APOE Summary Score 0; Summary Score system respectively assigns +1, 0, or 21 per E2, E3, or E4 allele of an individual with
genotypes (and scores) of: E2/E2 (+2), E2/E3 (+1), E2/E4 (0), E3/E3 (0), E3/E4 (21), E4/E4 (22).
doi:10.1371/journal.pone.0004787.t002
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in essential hypertensive individuals when on a low sodium diet
but not when on a normal-high sodium diet [44]. It was postulated
that the Trp polymorphism may be associated with increased GFR
which balances the increased sodium reabsorption [45]. This
hyperfiltration might lead to steeper decline in renal function over
time, especially in the presence of renal disease. In contrast, we
found an apparent protective effect of the alpha-adducin Trp
polymorphism on renal function decline. Perhaps this polymor-
phism, which confers a greater sodium resorptive capacity, may
protect against volume depletion and subsequent stimulation of
the RAS system.
Epsilon 4 apolipoprotein is defined by the presence of both the
344C and 472C polymorphisms in the APOE gene. This variant
has been associated with a reduced risk of adverse renal outcomes
when compared with Epsilon 3 (334T, 472C) and Epsilon 2 (334T,
472T) apolipoprotein, including a 40% reduction in risk for the
development of chronic kidney disease (RR=0.60, 95% CI 0.43–
0.84) in the AtherosclerosisRisk in Communities (ARIC)study [10].
Also, the time lag from identifiable onset of diabetes to initiation of
permanent hemodialysis was two-fold higher in apoE4 carriers than
the rate in non-apoE4 carriers among non-insulin dependent
diabetics [46]. The frequencies of apolipoprotein E variants in our
population were similar to the ARIC population. However, the
ARICstudyfoundthe strongestassociationsbetweenapoEtypeand
their endpoint, progression of chronic kidney disease, among the
African American subgroup, with a non-significant result for the
Caucasians. Our analysis used the summary score schema from the
ARIC study, but we found that risk of renal function decline did not
significantly increase with increasing summary score. The null
findings in our primarily Caucasian population more closely reflect
the results of the ARIC Caucasian subgroup. Also, the endpoint
analyzed for ARIC study was determined by ICD coding of
hospitalizations, rather than a measured creatinine value, for over
half (55.7%) of their subjects withthis outcome. The outcome in our
study was strictly based on eGFR change over time and may in part
account for our different results.
Because our participants were all female and Caucasian, the
genotype frequencies and results may not be generalizable to other
populations. Our population is generally healthy and has a low rate
of both baseline chronic kidney disease and diabetes, two groups in
which much of the prior genetic studies of renal outcomes had been
performed. The outcome was based on only two measurements of
serum creatinine separated by 11 years. Although there was likely
misclassification of GFR due to limitations of the MDRD equation
in individuals with near normal renal function, our study was large
and the duration of follow-up was long; therefore, it is unlikely that
we missed large associations. A third creatininemeasurement would
reduce variability in the estimate of change in renal function over
time. Larger studies will be needed to examine gene-gene and gene-
environment interactions.
In contrast to many genetic studies (such as genome wide
association studies), we selected these genes with specific a priori
hypotheses and thus believe it is justified to use the traditional level
of statistical significance (p,0.05). We acknowledge, however, that
in the absence of highly statistically significant results (on the order
of p,10
23), these associations should be carefully interpreted, and
replication in separate studies is necessary. The results would no
longer be considered statistically significant if the p-values were
adjusted for multiple comparisons.
Conclusion
Genetic polymorphisms in the angiotensinogen, angiotensin
type 1 receptor and alpha-adducin genes were associated with the
rate of renal function decline in our population. Other genetic
variants, including the ACE insertion/deletion, were not associ-
ated with renal function decline. Genetic variants may contribute
to loss of renal function in the general female Caucasian
population.
Methods
Study Population
The Nurses’ Health Study (NHS) began in 1976, when 121,700
female nurses 30 to 55 years of age completed a detailed
questionnaire regarding health-related information. Since then,
subsequent questionnaires updated information on lifestyle factors
and new medical diagnoses every 2 years. The participants in the
current study were part of a substudy designed to assess the
association between analgesic use and change in renal function
[47]. Briefly, we limited our study sample to the 32,826
participants who provided a blood sample in 1989. Women were
excluded from this initial blood collection if they had a history of
either cancer (except non-melanoma skin cancer) or cardiovascu-
lar disease (myocardial infarction, angina, stroke, or transient
ischemic attack). The characteristics of the women who provided
blood samples were similar to those of the total cohort in terms of
prevalent hypertension, age, weight, diabetes mellitus, and
hyperlipidemia, but those who provided blood samples were less
likely to be active smokers.
The population was then further limited to 3,123 women who
answered a supplementary questionnaire about analgesic use and
who provided a second blood sample in 2000, and to 2691 women
who had serum creatinine measured on both blood samples. The
population was further restricted to Caucasians in an effort to limit
population admixture, leaving a final study population of 2578
women. The institutional review board at Brigham Women’s
Hospital approved this study. No written informed consent was
required for this study by the IRB.
Blood Collection
Each blood collection kit contained all the necessary instructions
and supplies to have blood drawn and mailed back to our
laboratory with an ice pack. The samples were returned to our
laboratory via overnight courier; over 95% of the samples arrived
within 24 hours of being drawn. Upon arrival in our laboratory,
the chilled blood samples were centrifuged in a refrigerated unit
and blood components aliquotted in cryotubes that are stored in
the vapor phase of liquid nitrogen freezers; the highest
temperature is 2130uC. After extraction, the DNA obtained from
the buffy coats is well preserved. Neither the transport nor the
delay in processing appreciably decreased the amount of DNA
recovered [48].
Genotyping
Polymorphisms were selected because of their relation to the
RAS or proposed association with renal function decline. These
included two angiotensinogen polymorphisms, AGT M235T
(rs699) and AGT A-20C (rs5050), the angiotensin converting
enzyme insertion/deletion polymorphism (ACE I/D, no rs
number), the angiotensin II type 1 receptor A1166C polymor-
phism (AT1R A1166C, rs5186), and the aldosterone synthase T-
344C polymorphism (AS T-344C, rs1799998). All women in the
study were also genotyped for the alpha adducin G460W
polymorphism (rs4961) and the APOE C334T (rs429358) and
C462T (rs7412) polymorphisms, which determine apolipoprotein
E types 2, 3, or 4. Genotyping was performed at the Harvard/
Partners Genotyping Facility using Taqman or Sequenom. Failure
Genetics and Renal Function
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%, which was the failure rate for ACE I/D. We tested for
deviations from Hardy-Weinberg equilibrium for each SNP using
the Chi-square test and there were no substantial deviations
(P$0.04; Table 1).
Assessment of Renal Function
In 2001, baseline and follow-up blood samples from 1769
participants were thawed and sent for measurement of creatinine.
Both samples from each woman were run in the same laboratory
batch. Creatinine was measured by a Hitachi autoanalyzer using a
modified kinetic Jaffe reaction. The overall coefficient of variation
of the masked quality control samples was 10%. In 2005,
additional blood samples were thawed and sent for measurement
of creatinine using the above protocol to achieve the study
population of 2578 Caucasian women. The overall coefficient of
variation for creatinine of masked quality control samples for this
group was also 10%.
Glomerular filtration rate was estimated using the Modification
of Diet in Renal Disease (MDRD) formula [49]. The simplified
MDRD formula has been found to vary most from measured GFR
in individuals with normal or near normal renal function, i.e.
$60 ml/min/1.73 m
2. However, given the impracticalities of
directly measuring GFR in large cohort studies, the MDRD
formula appears to provide the best available estimate and has
been used successfully in several studies [50,51]. The MDRD
formula for Caucasians is creat
21.154*age
20.203*0.742.
Statistical analysis
Estimated GFR (eGFR) was calculated for each woman at the
beginning and end of the 11 year time period. The primary
outcome was a $25% decline in eGFR from baseline. Logistic
regression was used to examine the associations between genotype
and risk of eGFR decline of $25%. The secondary outcome was
absolute change in eGFR from baseline. Linear regression was used
to examine the associations between genotype and this change.
APOE variation was modeled with a summary score model,
which had been used in a prior study of genotype and chronic
kidney disease [10]. This genotypic scoring system respectively
assigns +1, 0, or 21 per E2, E3, or E4 allele of an individual with
genotypes (and scores) of: E2/E2 (+2), E2/E3 (+1), E2/E4 (0), E3/
E3 (0), E3/E4 (21), E4/E4 (22). Summary scores increase power
in modeling genetic exposures [52]. The reference group for the
APOE analysis was summary score 0. For all other polymor-
phisms, the genotype that a priori was hypothesized to confer the
lowest risk of renal function decline was used as the reference
group. For example, if for an allele p/q the q allele was
hypothesized to be associated with faster renal function decline,
then the p allele was used as the referent group. Genotype – renal
function associations were analyzed in three ways: per additional
risk allele (3 categories including pp as the reference group, pq,
and qq); recessive model (pp and pq combined as the reference
group); and a dominant model (pp as the reference group, with pq
and qq combined as the comparison group). Possession of a
particular polymorphism was assumed to be an inherent attribute
that would not be confounded by dietary or demographic factors.
Given this assumption, the primary models were adjusted for age
alone. However, genotypes that influence the risk of hypertension
could also influence the rate of renal function decline, thus
hypertension could be along the causal pathway between genotype
and rate of renal function decline. We therefore performed
additional analyses that adjusted for hypertension, as well as
diabetes mellitus and smoking. No adjustment was made for
multiple comparisons because each SNP was selected with an a
priori hypothesis. Odds ratios (OR) and 95% confidence intervals
(95% CIs) were calculated for all polymorphisms.
We also examined potential interactions with BMI (,25 kg/m
2
and $25) and history of hypertension (yes/no) [53].
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